Literature DB >> 7680330

Variability in the expression of a beta 2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon.

L García-Buey1, M López-Botet, A García-Sánchez, M A Balboa, J Aramburu, C García-Monzón, A Acevedo, R Moreno-Otero.   

Abstract

Cytotoxic CD8+ T lymphocytes recognize viral antigens in the context of human leukocyte antigen class I molecule coexpression by target cells. Analysis of beta 2-microglobulin reactivity is useful in evaluating changes in human leukocyte antigen class I antigen distribution. In this study we analyzed liver biopsy specimens obtained from 15 patients with chronic active hepatitis type C who underwent a clinical trial with recombinant interferon-alpha 2b. We comparatively studied by immunohistochemical analysis the expression of human leukocyte antigen class I antigens in frozen liver samples obtained before entry in the protocol and in specimens taken 8 mo after initiation of treatment. Six normal liver samples were used as controls. For immunohistochemical analysis, a panel of several human leukocyte antigen class I monoclonal antibodies, specific for beta 2-microglobulin or different heavy-chain determinants, was used. In addition, we included a novel monoclonal antibody (HP-1H8), characterized in this report, which is specific for a distinct beta 2-microglobulin epitope. On entry, mean serum ALT was 240 +/- 89 IU/L and mean Knodell's index was 9.9 +/- 2.4, whereas at the time of the second biopsy mean values had diminished to 45 +/- 22 IU/L and 4.7 +/- 3.0, respectively. Liver sections from controls and patients expressed human leukocyte antigen class I light- and heavy-chain determinants in hepatocytes, biliary duct epithelium, sinusoidal lining cells and lymphocytes. Remarkably, the beta 2-microglobulin epitope recognized by the HP-1H8 monoclonal antibody was undetectable on hepatocytes from normal livers but clearly evident on hepatocytes from patients with chronic active hepatitis C before interferon treatment. Positive staining was more intense in areas of piecemeal and lobular necrosis. Double immunostaining with a CD2 monoclonal antibody demonstrated that labeling with HP-1H8 was predominantly associated with T-cell infiltration. Interestingly, the reactivity of HP-1H8 with hepatocytes was diminished or disappeared in specimens obtained during interferon treatment; the pattern of reactivity then resembled that of samples from normal controls. Our data indirectly suggest that, in addition to the increased expression of human leukocyte antigen class I molecules on hepatocytes in viral infections, conformational changes may take place in these antigens. These changes can be revealed by immunostaining with the HP-1H8 monoclonal antibody. Interferon therapy could down-regulate this expression through its effect in reducing the histological activity resulting from the lysis of virus-infected hepatocytes by cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680330

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  Intrahepatic enhanced expression of beta2-microglobulin conformational epitope in acute liver allograft rejection: evidence of modulation by glucocorticoids.

Authors:  C García-Monzón; P L Majano; J A Solís; S Rodríguez; F Colina; M López-Botet; E Moreno-González; R Moreno-Otero
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

2.  The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation.

Authors:  R Mañez; R Mateo; J Tabasco; S Kusne; T E Starzl; R J Duquesnoy
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

3.  Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine.

Authors:  Ioannis-S Elefsiniotis; Antonios Moulakakis; Konstantinos-D Pantazis; Irene Glynou; Ioannis Ketikoglou; Elena Vezali; Helen Kada; Epameinondas Tsianos
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.